XIAP

Overview

XIAP (X-linked inhibitor of apoptosis protein, BIRC4) is a member of the IAP family that suppresses apoptosis by inhibiting caspase-3, -7, and -9. XIAP and related IAP proteins (cIAP1/2, encoded by BIRC2/BIRC3) are targeted by SMAC mimetics/antagonists in NPC.

Alterations observed in the corpus

• XIAP (along with BIRC2/BIRC3) is an inhibitor-of-apoptosis protein targeted by the IAP antagonist tolinapant in combination with radiotherapy in NPC. PMID:24952746
• Heterozygous germline R443P missense mutation diagnostic of X-linked lymphoproliferative syndrome 2 (XLP2) in a 6-year-old girl with hemophagocytic lymphohistiocytosis (HLH) and recurrent EBV infections PMID:28007021

Cancer types (linked)

• NPC — XIAP is a therapeutic target; tolinapant (IAP antagonist) + radiotherapy is under clinical investigation. PMID:24952746

Co-occurrence and mutual exclusivity

• No co-occurrence or mutual exclusivity data reported in the current corpus.

Therapeutic relevance

• Tolinapant (SMAC mimetic/IAP antagonist targeting XIAP and cIAP1/2) + radiotherapy in NPC. PMID:24952746

Open questions

• Clinical efficacy and biomarker correlates of IAP inhibition in NPC are not yet established; combination with radiotherapy is investigational.

Sources

• PMID:24952746

• PMID:28007021

This page was processed by entity-page-writer on 2026-05-15.